SUNPHARMA - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 2.3
Show all parameters (20 more)
🏭 Industry
The pharmaceutical industry generally exhibits high capital expenditure and R&D intensity, driving margins lower than some other sectors. However, brand-name drug manufacturers like Sun Pharma can maintain significant pricing power and generate consistent revenue streams, offering a degree of stability.
✅ Positive
Sun Pharma demonstrates strong profit growth with PAT increasing by 22.8% year-on-year, alongside a healthy cash flow driven by robust operational performance. The debt ratio of 0.61 indicates a conservative capital structure and substantial financial flexibility.
⚠️ Limitation
Despite positive earnings momentum, the high P/E ratio of 138 relative to the industry average of 34.6 suggests potential overvaluation and leaves limited room for future price appreciation without significant revisions to profitability expectations. The lack of dividend announcements introduces a risk factor; the company’s focus may be directed toward shareholder returns through share buybacks, but that is not certain or guaranteed.
🧾 Long-Term Outlook
We recommend an entry zone around 1,700 ₹ based on the current undervaluation relative to its peers, acknowledging the high P/E ratio. A long-term holding strategy should be considered assuming continued strong earnings growth continues with ongoing R&D investment and a focus on innovative product launches. This is a cautiously optimistic assessment considering Sun Pharma's underlying strength but emphasizes careful monitoring of future profitability trends.